

Sélection des publications

LES PUBLICATIONS PHARES DEPUIS 2011

- Baltus C, Jorda R, Marot C, Berka K, Bazgier V, Krystof V, Prié G, Viaud-Massuard M.C.
Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/cyclin E inhibitors.
Eur. J. of Med. Chem. 2016, 108, 701-719.
- Bejan-Angoulvant T, Ternant D, Daoued F, Medina F, Bernard L, Paintaud G, Mulleman D.
Relationship between infliximab serum concentrations and risk of infections in patients treated for inflammatory arthritis.
Ann Rheum Dis, accepté (A)
- Brachet G, Respaud R, Arnoult C, Henriquet C, Dhommée C, Viaud-Massuard MC, Heuze-Vourc'h N, Joubert N, Pugnière M, Gouilleux-Gruart V.
Increment in Drug Loading on an Antibody-Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro.
Mol Pharm. 2016 Mar 1. [Epub ahead of print]
- Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Spano JP, Moussata D, Terebonne E, Paintaud G, Ternant D.
Bevacizumab serum concentrations influence overall survival in metastatic colorectal cancer patients.
Clin Pharmacokinet, 2016 Jun 16. [Epub ahead of print]
- Dalloneau E, Baroukh N, Mavridis K, Mailet A, Gueugnon F, Courty Y, Petit A, Kryza T, Del Rio M, Guyetant S, Cadena Castaneda DC, Dhommée C, Arnoult C, Scorilas A, Gouilleux-Gruart V*and Heuzé-Vourc'h N*.
Down regulation of the neonatal fc receptor expression in non-small-cell lung cancer tissue is associated with a poor prognosis.
Oncotarget, 2016, accepté
- Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Germing U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche (FISMonlus), and Düsseldorf MDS Registry.
Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.
Br J Haematol. 2016 Jan 15. doi: 10.1111/bjh.13902. [Epub ahead of print]
- Rollin J, Pouplard C, Gruel Y
Risk factors for heparin-induced thrombocytopenia: Focus on Fc receptors.
Thromb Haemost. 2016 Jun 30;116(3). [Epub ahead of print]
- Ternant D, Arnoult C, Pugnière M, Dhommée C, Drocourt D, Perouzel E, Passot C, Baroukh N, Mulleman D, Tiraby G, Watier H, Paintaud G, Gouilleux-Gruart V.
IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.
J Immunol. 2016, 196 : 607-613
- Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I, Faure F, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Leguy-Seguín V, Rivière S, Corre R, Bailly S, Paintaud G.
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
MAbs. 2015, 7: 630-637
- Croix C, Prié G, Chaulet C, Viaud-Massuard MC.
Rhodium-Catalyzed 1,4-Addition of Arylboronic Acids to 3-Benzylidene-1H-pyrrolo[2,3-b]pyridin-2(3H)-one Derivatives.
J Org Chem. 2015, 80 : 3264-3269.
- Eid R, Demattei MV, Episkopou H, Augé-Gouillou C, Decottignies A, Grandin N, Charbonneau M.
Genetic inactivation of ATRX leads to a decrease in the amount of telomeric cohesin and of telomere transcription in human glioma cells.
Mol Cell Biol. 2015, 35: 2818-2830
- Gatault P, Brachet G, Ternant D, Degenne D, Récipon G, Barbet C, Gyan E, Gouilleux-Gruart V, Bordes C, Farrell A, Halimi JM, Watier H.
Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.
MAbs.2015, 7 : 1205-1211
- Karnes JH, Cronin RM, Rollin J, Teumer A, Pouplard C, Shaffer CM, Blanquicett C, Bowton EA, Cowan JD, Mosley JD, Van Driest SL, Weeke PE, Wells QS, Bakchoul T, Denny JC, Greinacher A, Gruel Y, Roden DM.
A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record.
Thromb Haemost. 2015, 113: 772-781
- Plas A, Martin C, Joubert N, Viaud-Massuard MC.
Palladium-Catalyzed Amination of N-Free 2-Chloro-7-azaindole.
Org Lett. 2015, 17 : 4710-4713

- Rollin J, Pouplard C, Cheng Sung H, Leroux D, Saada A, Gouilleux-Gruart V, Thibault G, Gruel Y. Increased risk of thrombosis in FcRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2. *Blood*. 2015,125 : 2397-2404
- Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerré T, Xavier LL, Vittecoq O, Goupille P, Mulleman D, Paintaud G. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. *Br J Clin Pharmacol*. 2015, 79 : 286-297.
- Ternant D, Berkane Z, Picon L, Gouilleux-Gruart V, Colombel JF, Allez M, Louis E, Paintaud G. Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease. *Clin Pharmacokinet*. 2015, 54 : 551-562
- Ducourau E, Ternant D, Lequerré T, Fuzibet P, Le Loët X, Watier H, Goupille P, Paintaud G, Vittecoq O, Mulleman D. Towards an individualised target concentration of adalimumab in rheumatoid arthritis. *Ann Rheum Dis*. 2014, 73: 1428-1429
- Lajoie L, Congy-Jolivet N, Bolzec A, Gouilleux-Gruart V, Sicard E, Sung HC, Peiretti F, Moreau T, Vié H, Clémenceau B, Thibault G. ADAM17-Mediated Shedding of FcRIIIA on Human NK Cells: Identification of the Cleavage Site and Relationship with Activation. *J Immunol*. 2014, 192: 741-751
- Ternant D, Büchler M, Thibault G, Ohresser M, Watier H, Lebranchu Y, Paintaud G. Influence of FcRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients. *Pharmacogenet Genomics*. 2014, 24 : 26-34
- Desbourdes L, Ishac N, Charbonnier T, Iltis A, Ducrocq E, Herault O, Gyan E, Domenech J. Integrity and Cell Cycle Of Leukemic Cells Are Modified By Mesenchymal Stem Cells From Healthy Individuals and AML Patients *Blood*. 2013, 122 : 21
- Mélet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G. Rituximab-induced T-cell depletion in patients with rheumatoid arthritis: Association with clinical response. *Arthritis Rheum*. 2013, 65: 2783-2790
- Rollin J, Pouplard C, Leroux D, May MA, Gruel Y. Impact of polymorphisms affecting the ACP1 gene on levels of antibodies against platelet factor 4-heparin complexes. *J Thromb Haemost*. 2013,11 : 1609-1611
- Cholez E, Debuyscher V, Bourgeois J, Boudot C, Leprince J, Tron F, Brassart B, Regnier A, Bissac E, Pecnard E, Gouilleux F, Lassoued K, Gouilleux-Gruart V. Evidence for a protective role of the STAT5 transcription factor against oxidative stress in human leukemic pre-B cells. *Leukemia* 2012, 26: 2390-2397
- Herault O, Hope KJ, Deneault E, Mayotte N, Chagraoui J, Wilhelm BT, Cellot S, Sauvageau M, Andrade-Navarro M, Hébert J, Sauvageau G. A role for GPx3 in activity of normal and leukemia stem cells. *J Exp Med* 2012, 209: 895-901
- Leroux D, Canépa S, Viskov C, Mourier P, Herman F, Rollin J, Gruel Y, Pouplard C. Binding of heparin-dependent antibodies to PF4 modified by enoxaparin oligosaccharides: evaluation by surface plasmon resonance and serotonin release assay. *J Thromb Haemost* 2012, 10: 430-436
- Rollin J, Pouplard C, Gratacap MP, Leroux D, May MA, Aupart M, Gouilleux-Gruart V, Payrastre B, Gruel Y. Polymorphisms of protein tyrosine phosphatase CD148 influence FcRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia. *Blood* 2012, 120 : 1309-1316
- Azzopardi N, Lecomte T, Ternant D, Boisdrion-Celle M, Piller F, Morel A, Gouilleux-Gruart V, Vignault-Desvignes C, Watier H, Gamelin E, Paintaud G. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. *Clin Cancer Res* 2011, 17 : 6329-6337
- Dhennin-Duthille I, Nyga R, Yahiaoui S, Gouilleux-Gruart V, Regnier A, Lassoued K, Gouilleux F. The tumor suppressor hTid1 inhibits STAT5b activity via functional interaction. *J Biol Chem* 2011, 286: 5034-5042
- Palazzoli F, Bire S, Bigot Y, Bonnin-Rouleux E. Landscape of chromatin control element patents: positioning effects in pharmaceutical bioproduction. *Nat Biotechnol* 2011, 29 : 593-597

SELECTION DES PUBLICATIONS 2016

- Baltus C, Jorda R, Marot C, Berka K, Bazgier V, Krystof V, Prié G, Viaud-Massuard M.C. Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/cyclin E inhibitors. *Eur. J. of Med. Chem*. 2016, 108, 701-719.
- Bejan-Angoulvant T, Ternant D, Daoued F, Medina F, Bernard L, Paintaud G, Mulleman D. Relationship between infliximab serum concentrations and risk of infections in patients treated for inflammatory arthritis. *Ann Rheum Dis*, accepted (A)

- Bernadou G, Campone M, Merlin JL, [Gouilleux-Gruart V](#), Bachelot T, Lokiec F, Rezai K, Arnedos M, Diéras V, Jimenez M, [Paintaud G](#), [Ternant D](#). Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. *Br J Clin Pharmacol*. 2016, 81 : 941-948
- Bonnier F, [Brachet G](#), Duong R, Sojinrin T, Respaud R, Aubrey N, Baker MJ, Byrne HJ, Chourpa I. Screening the low molecular weight fraction of human serum using ATR-IR spectroscopy. *J Biophotonics*. 2016 Aug 10. doi: 10.1002/jbio.201600015. [Epub ahead of print]
- [Bourgeois J](#), [Ishac N](#), Medrzycki M, [Brachet-Botineau M](#), [Desbourdes L](#), [Gouilleux-Gruart V](#), [Pecnard E](#), [Rouleux-Bonnin E](#), [Gyan E](#), [Domenech J](#), [Mazurier F](#), Moriggi R, Bunting KD, [Hérault O](#), [Gouilleux F](#). Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses. *Oncotarget*. 2016 Aug 22. doi: 10.18632/oncotarget.11480. [Epub ahead of print]
- [Brachet G](#), Respaud R, [Arnoult C](#), Henriquet C, [Dhommée C](#), [Viaud-Massuard MC](#), Heuze-Vourc'h N, [Joubert N](#), Pugnère M, [Gouilleux-Gruart V](#). Increment in Drug Loading on an Antibody-Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro. *Mol Pharm*. 2016 Mar 1. [Epub ahead of print]
- Bustany S, [Bourgeois J](#), Tchakarska G, Body S, [Hérault O](#), [Gouilleux F](#), Sola B. Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells. *Oncotarget*. 2016 Jun 7. doi: 10.18632/oncotarget.9901. [Epub ahead of print]
- Caulet M, [Lecomte T](#), Bouché O, [Rollin J](#), [Gouilleux-Gruart V](#), [Azzopardi N](#), Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Spano JP, Moussata D, Terebonne E, [Paintaud G](#), [Ternant D](#). Bevacizumab serum concentrations influence overall survival in metastatic colorectal cancer patients. *Clin Pharmacokinet*, 2016 Jun 16. [Epub ahead of print]
- Dalloneau E, [Baroukh N](#), Mavridis K, Maillat A, Gueugnon F, Courty Y, Petit A, Kryza T, Del Rio M, Guyetant S, [Cadena Castaneda DC](#), [Dhommée C](#), [Arnoult C](#), Scorilas A, [Gouilleux-Gruart V](#)*and Heuzé-Vourc'h N*. Down regulation of the neonatal fc receptor expression in non-small-cell lung cancer tissue is associated with a poor prognosis. *Oncotarget*, 2016, accepté
- Dannepond C, [Ternant D](#), Maruani A, Machet L, [Paintaud G](#), Samimi M. Serum infliximab concentrations and disease activity: a descriptive study of patients with psoriasis. *Br J Dermatol*. 2016, 174 : 198-200
- Darwiche W, [Bejan-Angoulvant T](#), Angoulvant D, Babuty D, Fauchier L. Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. Meta-analysis of observational analyses. *Thromb Haemost*. 2016 Sep 1;116(5). [Epub ahead of print]
- [Gyan E](#), Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Gerding U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche (FISMonlus), and Düsseldorf MDS Registry. Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis. *Br J Haematol*. 2016 Jan 15. doi: 10.1111/bjh.13902. [Epub ahead of print]
- Korkmaz B, Lesner A, Guarino C, Wysocka M, Kellenberger C, [Watier H](#), Specks U, Gauthier F, Jenne DE. Inhibitors and antibody fragments as potential anti-inflammatory therapeutics targeting neutrophil proteinase 3 in human disease. *Pharmacol Rev*. 2016, 68 : 603-630
- Lévi F, Karaboué A, Etienne-Grimaldi MC, [Paintaud G](#), Focan C, Innominato P, Bouchahda M, Milano G, Chatelut E. Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study. *Clin Pharmacokinet*. 2016 Jul 8. [Epub ahead of print]
- [Passot C](#), [Mulleman D](#), [Bejan-Angoulvant T](#), Aubourg A, Willot S, [Lecomte T](#), Picon L, [Goupille P](#), [Paintaud G](#), [Ternant D](#). The underlying inflammatory chronic disease influences infliximab pharmacokinetics. *MAbs*. 2016 Aug 9;1-10. [Epub ahead of print]
- Patin F, Baranek T, Vourc'h P, Nadal-Desbarats L, Goossens JF, Marouillat S, Dessein AF, Descat A, Madji Hounoum B, Bruno C, [Watier H](#), Si-Tahar M, Leman S, Lecron JC, Andres C, Corcia P, Blasco H. Combined metabolomics and transcriptomics approaches to assess the IL-6 blockade as a therapeutic of ALS: deleterious alteration of lipid metabolism. *Neurotherapeutics* 2016 Jul 21. [Epub ahead of print]
- [Pouplard C](#), [Gruel Y](#). A rapid test (STic Expert®) for the diagnosis of heparin-induced thrombocytopenia - response to De Cooman and Devreese *Br J Haematol*. 2016, 172 : 466-467
- Reboursiere E, Le Bras F, Herbaux C, [Gyan E](#), Clavert A, Morschhauser F, Malak S, Sibon D, Broussais F, Braun T, Fornecker LM, Garidi R, Tricot S, Houot R, Joly B, Abarah W, Choufi B16, Pham AD, Gac AC, Fruchart C, Marin E, Safar V, Parcelier A, Maisonneuve H, Bachy E, Cartron G, Jaccard A, Tournilhac O, Rossi C, Schirmer L, Martignoles JA, Gaulard P, Tilly H, Damaj G, Lymphoma Study Association Lysa Centers. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. *Oncotarget*. 2016 Jul 21. doi: 10.18632/oncotarget.10764. [Epub ahead of print]
- [Rollin J](#), [Pouplard C](#), [Gruel Y](#). Risk factors for heparin-induced thrombocytopenia: Focus on Fc receptors. *Thromb Haemost*. 2016 Jun 30;116(3). [Epub ahead of print]
- [Ternant D](#), [Arnoult C](#), Pugnère M, [Dhommée C](#), Drocourt D, Perouzel E, [Passot C](#), [Baroukh N](#), [Mulleman D](#), Tiraby G, [Watier H](#), [Paintaud G](#), [Gouilleux-Gruart V](#). IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.

Archives des publications

- [Sélection des publications 2015 \[PDF - 241Ko\]](#)
- [Sélection des publications 2014 \[PDF - 291Ko\]](#)
- [Sélection des publications 2013 \[PDF - 228Ko\]](#)
- [Sélection des publications 2012 \[PDF - 210Ko\]](#)
- [Sélection des publications 2011 \[PDF - 97Ko\]](#)

Liens utiles

- [BiblioVIE](#)
- [HAL \(Hyper Articles en Ligne\)](#)
- [PubMed](#)
- [SIGAPS](#)
- [Web of Knowledge](#)